Moderna (MRNA) Receivables (2017 - 2026)

Moderna (MRNA) has 10 years of Receivables data on file, last reported at $242.0 million in Q1 2026.

• Receivables for Q1 2026 came in at $242.0 million, down 13.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $242.0 million (down 13.88% YoY), and the FY2025 annual result was $410.0 million, down 45.84% from the prior year.
• Receivables retreated to $242.0 million in Q1 2026 per MRNA's latest filing, from $410.0 million in the prior quarter.
• Over five years, Receivables peaked at $3.2 billion in Q1 2022 and troughed at $199.0 million in Q1 2024.
• A 5-year average of $1.2 billion and a median of $1.2 billion in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2023 and 2025: Receivables slumped 90.01% in 2023, then jumped 46.58% in 2025.
• A 5-year view of Receivables shows it stood at $1.4 billion in 2022, then gained by 15.14% to $1.6 billion in 2023, then sank by 53.93% to $757.0 million in 2024, then slumped by 45.84% to $410.0 million in 2025, then sank by 40.98% to $242.0 million in 2026.
• Business Quant data shows MRNA's Receivables at $242.0 million in Q1 2026, $410.0 million in Q4 2025, and $2.0 billion in Q3 2025.